Fractyl Health Faces Shareholder Class Action Lawsuit
A class action lawsuit has been filed against Fractyl Health, Inc. concerning investors who experienced losses following disclosures about the company's Revita DMR therapy. The deadline to be appointed lead plaintiff is October 20, 2026.
Distribution: PR Newswire
Fractyl Health Faces Shareholder Class Action Lawsuit
A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) by the law firm Robbins LLP, which focuses on investor rights. The suit represents individuals and entities who purchased or acquired Fractyl Health securities between January 13, 2025, and January 29, 2026. The company is developing therapies for type 2 diabetes and obesity.
The litigation centers on the company's Revita DMR System, an investigational therapy. The complaint alleges that the company failed to provide investors with complete and accurate information regarding Revita's efficacy and its clinical and commercial prospects. The alleged misleading statements are said to relate to the performance of Revita in the REMAIN-1 Midpoint Cohort study.
Fractyl Health's stock experienced a significant decline on January 29, 2026, after the company released six-month data from the REMAIN-1 Midpoint Cohort study for its Revita DMR System. The disclosed results indicated less weight regain than anticipated, and the company stated the study design was not sufficiently powered for efficacy analysis. Additionally, the CEO acknowledged issues at one study site that may have impacted the results. Following these disclosures, the company's stock price fell sharply.
Robbins LLP is reminding investors that the deadline to file a motion to be appointed lead plaintiff in this class action is October 20, 2026. Investors who incurred substantial losses during the specified period are encouraged to contact the law firm for more information about their rights. Participation in the class action does not require investors to act as lead plaintiff and will not result in any cost to them, as the firm represents clients on a contingency fee basis.